Biomarker or molecular testing to help oncologists match patients with the best cancer treatment can be challenging in the community oncology setting and for patients in underserved communities. At present, patients with cancer in racially or ethnically underserved communities are not getting biomarker testing at the same rate as White patients in communities with greater access to care. Barriers to testing include insurance restrictions, conflicting guidelines, and the reliance of community oncologists on single-gene testing instead of multi-gene panels used more often by academic oncologists. In the multidisciplinary setting of community oncology, healthcare professionals (HCPs) would benefit from education on best practice models that provide cost-effective molecular testing services for the undertested underserved population, especially given that more recently U.S. Food and Drug Administration (FDA)-approved treatments require biomarker testing.
In this CME Outfitters recorded symposium expert faculty will evaluate the latest biomarker testing strategies in prostate, bladder, and lung cancer, discussing how to integrate all members of the interdisciplinary care team in community oncology settings, identifying root causes of health inequity in cancer care and how to incorporate strategies to address unconscious bias and provide the latest biomarker testing services in cancer care management.
At the conclusion of this activity, learners will be able to better:
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Managed care physicians and pharmacists, community oncologists, oncology physician associates (PAs) and nurse practitioners (NPs), oncology nurses, and oncology pharmacists
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.50 contact hours (0.15 CEUs) of continuing pharmacy credit (JA0007185-0000-24-102-H01-P).
This activity is designated for 1.50 contact hours.
California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education Credit for learning and change.
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until 10/22/2025. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Dr. Brixner reports the following financial relationships:
Advisory Board: Bayer and Jazz Pharmaceuticals, Inc.
Consultant: LEO Pharma; Millcrreek Outcomes Group, LLC; Sanofi; and Tandem Therapeutics
Grants: Dexcom, Inc.
Dr. Rivers reports the following financial relationships:
Stock Shareholder (ownership interest): Tempus AI, Inc.
Employment: Tempus AI, Inc.
Ms. Donaldson reports no financial relationships to disclose.
The following individuals have no financial relationships to disclose:
Alaa Bawaneh, MD, PhD (Peer Reviewer)
Andrea Edwards, PA-C (Peer Reviewer)
Mary Gleason, PhD, CHCP (Planning Committee)
Nichole Lainhart (Planning Committee)
David Modrak, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Call us at 877.CME.PROS (877.263.7767).
MMV-149-102224-90
